DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

<正>DB-1310 and trastuzumab synergistically inhibit breast cancer(BC) cell proliferation in vitro HER3 overexpression has been described in patients with HER2-positive BC1. We determined the levels of HER2 and HER3 expression in BC using RNA-seq data from 1,082 BC patient samples in the TCGA dataset and 67 BC cell lines in the CCLE database(Supplementary material 1). A positive correlation existed between HER2 and HER3 expression in the patient samples and cell lines with Pearson correlation coefficients of 0.27(P < 0.0001) and 0.59(P < 0.0001), respectively(Figure S1). This correlation suggests a potential synergistic role of HER2 and HER3 in BC tumorigenesis.